title: Re: Nizar M. Tannir, Eric Jonasch, Laurence Albiges, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN):A Randomized Multicenter Phase 2 Trial. Eur Urol 2016;69:866-74.
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: Yang
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
authors.forename: Lin
authors.initials: L
authors.lastname: Qi
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Electronic address: chenminfeng1999@163.com.
authors.forename: Minfeng
authors.initials: M
authors.lastname: Chen
mesh_terms: D002292:Carcinoma, Renal Cell; D000068338:Everolimus; D006801:Humans; D007211:Indoles; D007680:Kidney Neoplasms; D011446:Prospective Studies; D011758:Pyrroles; D000077210:Sunitinib
chemical_list: D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib